{
  "id": "5e30f23cfbd6abf43b000042",
  "type": "yesno",
  "question": "Is modified vaccinia Ankara effective for smallpox?",
  "ideal_answer": "Yes, modified vaccinia Ankara is effective for smallpox.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17977963",
    "http://www.ncbi.nlm.nih.gov/pubmed/26143613",
    "http://www.ncbi.nlm.nih.gov/pubmed/26380340",
    "http://www.ncbi.nlm.nih.gov/pubmed/15227622",
    "http://www.ncbi.nlm.nih.gov/pubmed/16840346",
    "http://www.ncbi.nlm.nih.gov/pubmed/28374245",
    "http://www.ncbi.nlm.nih.gov/pubmed/18683106",
    "http://www.ncbi.nlm.nih.gov/pubmed/25879867",
    "http://www.ncbi.nlm.nih.gov/pubmed/27146001",
    "http://www.ncbi.nlm.nih.gov/pubmed/17604541",
    "http://www.ncbi.nlm.nih.gov/pubmed/28256358",
    "http://www.ncbi.nlm.nih.gov/pubmed/27327616",
    "http://www.ncbi.nlm.nih.gov/pubmed/19093767",
    "http://www.ncbi.nlm.nih.gov/pubmed/23523410",
    "http://www.ncbi.nlm.nih.gov/pubmed/29652929",
    "http://www.ncbi.nlm.nih.gov/pubmed/26949713",
    "http://www.ncbi.nlm.nih.gov/pubmed/23523407"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29652929",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The three MVA lots induced equivalent antibody titers two weeks after the second vaccination, with seroconversion rates of 99\u00b78% (PRNT) and 99\u00b77% (ELISA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29652929",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: To guide the use of modified vaccinia Ankara (MVA) vaccine in response to a release of smallpox virus, the immunogenicity and safety of shorter vaccination intervals, and administration by jet injector (JI), were compared to the standard schedule of administration on Days 1 and 29 by syringe and needle (S&N).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28256358",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erratum: Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26949713",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27146001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN\u00ae) in 56-80-Year-Old Subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27327616",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Modified Vaccinia Ankara MVA-BN\u00ae is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27327616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: One or two doses of MVA were safe and immunogenic in a 56-80 years old vaccinia-experienced population. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27327616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results suggest that a single dose of MVA in a 56-80 years old population was well tolerated and sufficient to rapidly boost the long-term B cell memory response induced by a prior vaccination with a traditional smallpox vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27327616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified Vaccinia Ankara (MVA) poxvirus has been assessed for cardiac safety in a large placebo-controlled clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25879867",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Modified vaccinia Ankara (MVA) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a liquid formulation for subcutaneous (SC) administration at a dose of 1\u00d710(8) TCID50 in a volume of 0.5mL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26143613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18683106",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bavarian Nordic is developing IMVAMUNE, which is based on a live attenuated modified vaccinia Ankara virus, for the potential prevention of smallpox infection, particularly in those patients contraindicated to traditional smallpox vaccines, such as the immunocompromised and those with eczema or dermatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18683106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19093767",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Modified vaccinia Ankara: potential as an alternative smallpox vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15227622",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17604541",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Modified vaccinia Ankara: potential as an alternative smallpox vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15227622",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Modified vaccinia Ankara ( MVA ) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile ( SNS ) as a liquid formulation for subcutaneous ( SC ) administration at a dose of 1\u00d710 ( 8 ) TCID50 in a volume of 0.5mL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26143613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified vaccinia Ankara was safe and immunogenic in subjects infected with HIV and represents a promising smallpox vaccine candidate for use in immunocompromised populations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bavarian Nordic is developing IMVAMUNE , which is based on a live attenuated modified vaccinia Ankara virus , for the potential prevention of smallpox infection , particularly in those patients contraindicated to traditional smallpox vaccines , such as the immunocompromised and those with eczema or dermatitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18683106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One of the most advanced and most promising vectors is the attenuated , non-replicating poxvirus MVA ( modified vaccinia virus Ankara) , a safer derivative of the uniquely successful smallpox vaccine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified vaccinia virus Ankara ( MVA ) is a highly attenuated vaccinia virus that is under consideration as an alternative to the conventional smallpox vaccine Dryvax",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17977963",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified Vaccinia virus Ankara ( MVA ) is an attenuated derivative , also used in the smallpox eradication campaign and now being developed as a recombinant viral vector to produce vaccines against infectious diseases and cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28374245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While modified vaccinia virus Ankara ( MVA ) is currently in clinical development as a safe vaccine against smallpox and heterologous infectious diseases , its immunogenicity is likely limited due to the inability of the virus to replicate productively in mammalian hosts",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16840346",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified vaccinia Ankara was safe and immunogenic in subjects infected with HIV and represents a promising smallpox vaccine candidate for use in immunocompromised populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombinant viral vector to produce vaccines against infectious diseases and cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u2003Modified vaccinia Ankara was safe and immunogenic in subjects infected with HIV and represents a promising smallpox vaccine candidate for use in immunocompromised populations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26380340",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}